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CHAPTER ONE: INTRODUCTION AND AIMS OF PROJECT 
 
1.1 INTRODUCTION  
 
Malnutrition is a state in which a deficiency of energy, protein and other nutrients 
causes measurable adverse effects on tissue, body form, composition, function or 
clinical outcome. It is both a cause and a consequence of ill-health and is common 
nowadays. Since malnutrition increases a patient’s vulnerability to ill health, 
providing nutrition support to patients with malnutrition should improve outcomes 
but decisions on the most effective and safe means to do so are complex. 
Parenteral nutrition (PN) refers to the administration of nutrients by the intravenous 
route. It is usually administered via a dedicated central or peripheral placed line1. 
 
1.2 AIMS OF PROJECT 
 
The purpose of this rigorous thesis was to obtain more punctual information on 
stability of the vitamins in Intralipid® emulsion depending on different storage 
conditions and different time. There are two projects which were done. 
 
1. Stability of the fat-soluble and the water-soluble vitamins which were added 
to the Intralipid® emulsion, and stored in 50 ml Luer-Lock Syringes.  
 
Assessing the chemical and the physical stability was carried out after: 
 
 Zero time 
 7 days in a refrigerator followed by 24 hours and 48 hours storage at ambient 
temperature and protected from day-light. 
 14 days in a refrigerator followed by 24 hours and 48 hours storage at 
ambient temperature and protected from day-light. 
 29 days in a refrigerator followed 24 hours and 48 hours storage at ambient 
temperature and protected from day-light. 
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2. Ascorbic acid (AA) is rapidly oxidised, the oxidation of AA clearly proceeds to 
inactive products. There is potential appearance of oxalic acid (OA) in the 
mixture as an end stage degradation product2. The purpose of my 
investigation was to prove the presence of OA as a degradation product of 
AA dissolved in water after couple-day storage at ambient temperature via 
HPLC analysis. 
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CHAPTER TWO: THEORETICAL PART 
 
2.1 PARENTERAL NUTRITION 
 
PN has now become the accepted method for the prevention or correction of 
malnutrition in patients who cannot be provided with adequate nutrition by the 
gastro-intestinal route. PN is an alternative method of providing nutritional support 
for patients via the intravenous route, the order methods being by the oral or 
enteral route3.  
 
Awareness of malnutrition in hospital patients is now increasing and recently, the 
National Institute for Health and Clinical Excellence (NICE) has issued a guideline 
that all hospital patients should be screened to identify those who are 
malnourished or at risk of malnutrition, and that nutrition support should be 
considered in these patients4. This guideline recommends that all hospital 
inpatients on admission and all outpatients at their first appointment should be 
screened (weight, measured and have Body Mass Index (BMI) calculated).  
 
Malnutrition in hospitals is surprisingly common. Several studies have shown that 
up to 65% of patients admitted to medical and surgical wards are undernourished 
or become so during their stay. These patients are more likely to suffer from 
complications, they are more susceptible to infection and they experience delayed 
wound healing. Their mortality rates are higher and their stays in hospital longer. 
There is therefore increasing interest amongst health-care professionals in 
methods of providing nutritional support5.  
 
 
2.2 INDICATIONS FOR INTRAVENOUS NUTRITION 
 
This paragraph was discussed in Diploma thesis of Khýnová6 in detail.  
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2.3 COMPONENTS OF PN ADMIXTURES 
 
Mainly three macronutrients form PN admixtures. Namely: carbohydrates in the 
form of glucose, proteins as amino acid solutions, and fats in the form of lipid 
emulsions. Carbohydrates and fats provide the patients energy requirements. 
Included are the major electrolytes such as sodium, potassium, chloride, calcium, 
magnesium and phosphate. The addition of micronutrients, including vitamins and 
trace elements, make a PN complete7. For mixtures which contain all described 
nutrients is used the term total parenteral nutrition (TPN). TPN problems were 
specified in Diploma thesis Khýnová6 in detail.  
 
2.3.1 Lipids 
 
Lipids are very important energy substances and provide caloric requirements. 
They also serve as a source of essential fatty acids, such as linoleic and linolenic 
acid, which are necessary for the functioning of all tissues7. Lipid requirement is 
about 1 – 1.5 g/ kg/ day in healthy adults8.  
 
 
Currently available intravenous emulsions consist of 10% or 20% emulsions of 
soybean or safflower oil. These are long-chain triglycerides (LCT), rich in omega-6 
polyunsaturated fatty acids (PUFA) 7. New lipid emulsions are created medium-
chain triglycerides (MCT) derived from palm kernel and coconut oil. MCT 
emulsions have to be administered either at very slow rates or together with LCT 
because of undesirable symptoms. Administration of an MCT/LCT mixture 
revealed in many cases advantages over an LCT. The current interest is in the use 
of fish oil and olive oil lipid emulsions. Olive oil contains a high level of 
monounsaturated fatty acids (MUFA) and fish oil is rich in n-3 fatty acids. There is 
the claim that n-3 fatty acids have anti-inflammatory and immunomodulatory 
effects9.  
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2.3.2 Proteins 
 
Proteins are large organic compounds made of amino acids arranged in a linear 
chain and joined together by peptide bonds. Therefore they are a source of amino 
acids. Traditionally, amino acids are classified into essential and non-essential. 
Essential amino acids in adults include histidine, leucine, isoleucine, lysine, 
methionine, phenylalanine, threonine, tyrosine, valine, tryptophan. Some of the 
non-essential amino acids are alanine, arginine, glycine, glutamate, glutamine, 
serine and taurine10.  
Essential amino acids must be provided in the diet and should provide about 40 % 
of the total amino acid nitrogen. A daily intake of 12 – 16 g of nitrogen has been 
found to be adequate for most patients11. Some sick patients may be unable to 
synthesize amino acids which are considered to be non-essential in normal 
subjects. For example, histidine may not be synthesized in adequate amounts in 
patients with renal failure12. 
 
2.3.3 Carbohydrates 
 
Dietary carbohydrates usually provide between 40 – 70 % (currently 
recommended 50 – 55 %) of our total daily energy intake. Glucose is the main 
source of readily available energy13. Adult glucose requirements in healthy 
subjects can be set at 4 – 5 g/ kg/ day, equivalent to 50 % of the total energy 
requirement8.  
 
Glucose is supplied intravenously in the exact chemical form in which it is 
absorbed from the intestine. This glucose requirement is unique to humans and is 
about 145 – 160 g per day. Injured or septic patients may require more glucose 
than normal patients9.   
 
2.3.4 Fluids and Electrolytes 
 
The intake of fluid and electrolytes is an integral part of nutritional support. The 
calculation of appropriate requirements is necessary because electrolytes 
abnormalities may cause physiological and functional problems for the patients. 
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Potassium, sodium, magnesium, calcium and phosphate are some of the major 
electrolytes required14. Daily requirements of each ion can vary widely, depending 
on the disease state and may be very high2.  
 
2.3.5 Micronutrients 
 
Micronutrients are main classes of nutrient substances required in the diet in very 
small amount. These are the essential inorganic micronutrients otherwise the trace 
elements, and the vitamins or the essential organic micronutrients. The trace 
elements include zinc, cooper, selenium, manganese, chromium, molybdenum, 
iron, iodine and fluorine.  
 
There are two main functions of micronutrients. Firstly they act as cofactors or 
coenzymes in enzyme catalyzed reactions. In general, the water-soluble vitamins 
have roles as coenzymes, taking an active part in enzyme catalyzed reactions. For 
both of these groups of substances, enzyme activity may be modulated by the 
availability of the micronutrient. In disease states, the metabolism of the major 
substances is significantly increased, and therefore the requirements for 
micronutrients are also increased. A second, micronutrient’s role is as part of the 
free-radical scavenging system. Oxidative metabolism generates a family of 
reactive oxygen species (superoxide, hydroxyl) and these have the potential to 
cause significant chemical damage15. Both vitamins and trace elements are 
discussed under Vitamins (see 2.4). 
 
2.4 VITAMINS  
 
Vitamins are organic, low molecular weight substances that have key roles in 
metabolism. The vitamins are required in only small amounts in the diet because 
they are highly specific. They are classified according to their solubility into two 
groups - the fat-soluble vitamins and the water-soluble vitamins. The fat-soluble 
vitamins include vitamins A, E, D, K these are soluble in non-polar solvents and 
have the potential for storage in the body. The water-soluble vitamins include 
ascorbic acid and the vitamin B group. They are soluble in polar solvents and are 
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not stored in the body. They are excreted in the urine when present is excess of 
the body’s needs16. 
 
Following paragraphs describe chemical structure of single vitamins and their 
degradation potential as well. Vitamins were discussed in Diploma thesis of 
Khýnová6 in detail. See mentioned thesis for detailed information.  
 
2.4.1. Thiamine (Vitamin B1) 
 
 
 
Figure 2.1:  Chemical Structure of Thiamine 
 
Vitamin B1 is degraded by a number of mechanisms. It is increasingly unstable as 
the pH rises and is decomposed by oxidizing or reducing agents. The reduction is 
caused in particular by sodium metabisulfite used as an antioxidant in some amino 
acids infusions. The route of degradation is showed at Figure 2.2. The rate of this 
cleavage increases with increased pH to a maximum rate of pH 6.  A couple 
studied confirmed that bisulfite at concentrations above 1 mmol/L caused thiamine 
degradation. There are some losses of thiamine after exposure to direct sunlight, 
but no significant losses after exposure to indirect daylight or fluorescent light17. 
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Figure 2.2: Thiamine Degradation Pathway 
 
 
 
 
 
2.4.2 Riboflavin (Vitamin B2) 
 
 
Figure 2.3: Chemical Structure of Riboflavin 
 
 
 
Riboflavin has been reported to accelerate the photodegradation of certain amino 
acids. Enhanced degradation of methionine, tryptophan, proline, and tyrosine 
accelerated in the presence of riboflavin was reported during simulated infusion 
over a 24 hours period. Riboflavin is degraded by exposure to daylight, although it 
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is less sensitive than retinol. In contrast the vitamin was not degraded by exposure 
to fluorescent light17. 
 
 
 
2.4.3 Niacin (Vitamin B3) 
 
 
 
Figure 2.4: Chemical Structure of Nicotinic Acid 
 
The term niacin is the generic descriptor for nicotinic acid (pyridine-3-carboxylic 
acid) (Figure 2.4) and nicotinamide (nicotinic acid amide).  
 
Both nicotinic acid and nicotinamide are very stable in dry form, but in solution 
nicotinamide is hydrolyzed by acids and bases16.  
 
 
2.4.4 Pyridoxine (Vitamin B6) 
 
 
 
Figure 2.5: Chemical Structure of Pyridoxine 
 
Vitamin B6 is the generic descriptor for all 3-hydroxy-2-methylpyridine derivatives.  
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Allwood2 reported that pyridoxine is also light sensitive although degradation is far 
less than is observed with vitamin A or riboflavin. Direct sunlight causes loss of 
pyridoxine, but it is stable during exposure to indirect daylight or fluorescent light.17 
 
 
2.4.5 Folic Acid 
 
 
 
Figure 2.6: Chemical Structure of Folic Acid 
 
Folic acid is also known as pteroylglutamic acid (PteGlu), consists of a pteridine 
nucleus coupled to para-aminobenzoic acid (PABA), to become pteroic acid 
molecule, and conjugated with one to seven molecules of L-glutamic acid16.  
 
Folic acid (FA) is insoluble in water and injections are formulated as sodium salt at 
pH above 8.0. After addition to TPN mixtures, there is a danger of free folate 
precipitation, especially in solutions below pH 4.5 – 5. FA in PN mixtures is 
compatible with plastic bags and sets. FA has been shown to be stable after 
exposure to indirect or direct daylight, and fluorescent light as well. Most folates 
are easily oxidized and, therefore, are unstable to oxidation under aerobic 
conditions of storage. Under such conditions tetrahydrofolic acid (FH4) derivatives 
can readily be oxidized to the corresponding derivatives of dihydrofolic acid (FH2) 
or folic acid17.  
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2.4.6 Vitamin B12  
 
Figure 2.7: Chemical Structure of Cyanocobalamin 
 
Vitamin B12 is an octahedral cobalt complex consisting of a porphyrin-like, cobalt-
centered macroring (called corrin ring), a nucleotide, and a second cobalt-bound 
group (e.g. H2O, CN
-, CH3). Vitamin B12 is the generic descriptor for all corrinoids 
(i.e. compounds containing the corrin ring) exhibiting the qualitative biological 
activity of cyanocobalamin (Figure 2.7)16. 
 
Vitamin B12 is very stable in both crystalline form and aqueous solution. However, 
the cobalamins are unstable to light16.  
 
 
 
 
2.4.7 Pantothenic Acid 
 
 
Figure 2.8: Chemical Structure of Pantothenic Acid 
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Pantothenic acid is yellow, viscous oil. Its calcium and other salts, however, are 
colourless crystalline substances. Each form is soluble in water and ethanol. 
Aqueous solutions of pantothenic acid are unstable to heating under acidic or 
alkaline conditions16. 
 
 
2.4.8 Biotin 
 
Figure 2.9: Chemical Structure of Biotin 
 
Biotin is formerly known as vitamin H.  
 
Biotin is unstable to oxidizing conditions and, therefore, is destroyed by heat, 
especially under conditions that support lipid peroxidation16. 
 
 
 
2.4.9 Ascorbic Acid (Vitamin C) 
 
Figure 2.10: Chemical Structure of Ascorbic Acid 
 
Vitamin C is the generic descriptor for all compounds that exhibit the biological 
activity of ascorbic acid (Figure 2.10). The oxidized form of this compound is called  
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dehydroascorbic acid. Ascorbic acid (AA) is a dibasic acid. It forms salts, the 
aqueous solutions of which are strongly acidic. AA is a strong reducing agent and 
is oxidized under mild conditions to dehydroascorbic acid via the radical 
intermediate semidehydroascorbic acid. The three forms (AA, 
semidehydroascorbic acid, dehydroascorbic acid) compose a reversible redox 
system. It is therefore an effective quencher of free radicals such as singlet 
oxygen. It reduces ferric (Fe3+) to ferrous (Fe2+) iron and the superoxide radical 
(O2
.-) to H2O2 and is oxidized to monodehydroascorbic acid in the process
16. 
 
 
Ascorbic acid is the least stable of all the vitamins added to TPN mixtures, 
although degradation of AA depends on a number of inter-related factors. AA is 
oxidized in aqueous solution by reaction with dissolved oxygen. The rate of 
degradation depends on various aspects of the solution. The most important 
factors are dissolved oxygen and the presence of catalysts, especially copper 
ions. Slow loss of vitamin C occurs during clinical administration of TPN mixtures if 
TE, especially copper, are excluded. If cooper is included, oxidation is accelerated.  
The total amount of AA degraded depends on the oxygen content of the infusion 
and the volume of air remaining in the bag. A second stage of vitamin C 
degradation occurs due to the permeation of oxygen through the plastic. Some 
degradation will be also occurs in the administration set for the same reasons2. 
Allwood2 also reported that cysteine and cystine inhibit the catalytic effect of 
copper, therefore, if infusion includes amino acids, degradation rates can be lower.  
 
 
 
Figure 2.11: The Degradation of AA in the Presence of Oxygen 
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Dehydroascorbic acid is metabolically active. Therefore if the reaction proceeds 
only to this point, the availability of vitamin C is unaffected. The oxidation of AA 
clearly proceeds rapidly to inactive products. There is the potential appearance of 
oxalic acid (OA) in the mixture as end stage degradation product. The potential 
toxicity of this reaction may be significant2. In vivo OA is normally excreted in urine 
as a waste product of intermediary metabolism, but may precipitate with calcium in 
urine or soft tissues. Calcium oxalate precipitation deposition plays a role in 
urolithiasis, renal failure and the systemic oxalosis of certain inborn errors of 
metabolism. In patients receiving long-term TPN has been reported hyperoxaluria, 
elevated serum oxalate concentration, and systemic oxalosis because of 
degradation of parenteral AA. Oxalogenesis from AA oxidation in TPN solutions 
has been reported to cause catheter occlusion. Oxalate itself is not stable in dilute 
solution and degrades to carbon dioxide and formic acid under UV light18. 
 
2.4.10 Vitamin A  
 
 
Figure 2.12: Chemical Structure of Retinol 
 
Vitamin A is the generic descriptor for compounds with the qualitative biological 
activity of retinol (Figure 2.12). They are called retinoids16.  
 
Retinol is the most light-sensitive of the vitamins17. Retinol is known to be rapidly 
broken down by exposure to UV light. Therefore, daylight causes rapid 
degradation2. Photolysis proceeds both in the bag and during passage through the 
administration set. Administration in a room with only artificial lighting will lead to 
minimum degradation. Sorption of retinol has been reported, but it depends on the 
ester used. Whereas the acetate ester binds strongly to PVC bags and 
administration sets, the palmitate ester shows no evidence of binding to plastics 
used to store or administer PN17. The presence of amino acids and fat emulsion in 
the bag affords considerable protection2. 
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2.4.11 Vitamin D 
 
                      
 
Figure 2.13: Chemical Structure of Figure 2.14: Chemical Structure of  
Ergocalciferol Cholecalciferol    
 
 
Vitamin D is the generic descriptor for all steroids exhibiting qualitatively the 
biological activity of cholecalciferol. Ergocalciferol (Figure 2.13) (vitamin D2) is 
found in plants, fungi, and lichens while cholecalciferol (Figure 2.14) (vitamin D3) is 
widely distributed in animals16.  
 
Gillis19 reported that vitamin D may be strongly bound to plastic. Sorption to the 
administration set and bag can be significant.  
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2.4.12 Vitamin E 
 
 
Figure 2.15: Chemical Structure of -tocopherol 
 
 
Vitamin E is the generic descriptor for all tocoretinol derivates that exhibit 
qualitatively the biological activity of -tocopherol (Figure 2.15).  
 
Tocopherol appears to be relatively stable in PN mixtures17. But Gillis19 reported 
that vitamin E and D may be strongly bound to plastic. Sorption to the 
administration set and bag can be significant. Vitamin E together with Vitamin A 
are the most light sensitive vitamins. Vitamin E degrades by photo-oxidation20. 
 
 
 
2.4.13 Vitamin K 
 
Vitamin K is the generic descriptor for 2-methyl-1,4-naphthoquinone and all of its 
derivatives exhibiting qualitatively the biological activity of phylloquinone. Naturally 
occurring forms of the vitamin have unsaturated isoprenoid side chain at C-3 of the 
naphthoquinone nucleus. The phylloquinone group includes forms with phytyl side 
chain and is called vitamin K1 
16 (Figure 2.16). The menaquinone group have side 
chain composed of a varying number of isoprenoid residues. The menaquinone 
(Figure 2.17) is called vitamin K2 and is synthesized by bacteria. The compound 
without a side chain is called menadione. It does not exist naturally and is the 
compound of commerce, because is made in several forms (e.g. menadione 
sodium bisulfite complex, menadione dimethylpyrimidinol bisulfite)16. 
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Figure 2.16: Chemical Structure of Phylloquinone 
 
 
Figure 2.17: Chemical Structure of Menaquinone 
 
 
 
Table 2.1: Daily Parenteral Vitamin Requirements in Adults15 
 
Vitamins Adults parenteral requirements 
Vitamin A 1000 µg 
Vitamin D 5 µg 
Vitamin E 10 mg 
Vitamin K 150 µg 
Thiamine 3.0 mg 
Riboflavin 3.6 mg 
Pyridoxine 4.0 mg 
Niacin 40 mg 
B12 5 µg 
Folic acid 400 µg 
Biotin 60 µg 
Ascorbic acid 100 mg 
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Commercial vitamins for PN are commonly available as multivitamin formulations 
such as Solvitio® N (Fresenius Kabi), Cernevit® (Baxter), Vitlipid® N Adult 
(Fresenius Kabi) and Vitlipid® N Infant (Fresenius Kabi) injections. Multiple TE are 
now available in a formulation such as Additrace® (Fresenius Kabi) and Decan® 
(Baxter) for adults, and Peditrace® (Fresenius Kabi) for paediatrics7. 
 
 
 
2.5 POTENTIAL INTERACTIONS OF COMBINED TPN MIXTURES IN BIG 
BAGS 
 
Chemically unstable mixture with many possible reactions occurring may be 
caused by mixing of TPN components, which include glucose, lipids, amino acids, 
electrolytes, vitamins and TE21. These reactions include precipitation and 
degradation of particular compounds. Exposure to light may cause degradation 
while temperature changes can result in precipitation. Significant loss of stability or 
precipitation could be caused by pH changes. The filling process is important as 
well because causes aeration of solutions and increasing concentrations of 
dissolved oxygen. Poor mixing can lead to local concentration effects resulting in 
chemical reaction2. 
 
2.5.1 Amino Acid Stability  
 
Amino acids retain their stability after dilution in TPN mixtures for at least 28 days 
if stored in the refrigerator. They are also stable during exposure to normal levels 
of artificial light or daylight. However, exposure to intense artificial light from a 
phototherapy unit in neonatal care may cause accelerated degradation of glycine 
and leucine. In the presence of riboflavin, photo-oxidation of several amino acids is 
accelerated2.  
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2.5.2 Vitamin Stability 
 
Vitamins are believed to be among the least stable ingredients in PN mixtures, and 
it is recommended that they should be added immediately before commencing 
infusion or that infusion should be commenced within 24 – 28 hours of addition. 
Some vitamins can undergo degradation during administration. The major physico-
chemical considerations are exposure to light, the type of plastic used to 
manufacture the PN container and infusion equipment, and storage temperature. 
The most important cause of vitamin losses in PN mixtures is chemical 
degradation17. Stability of particular vitamins was discussed in detail under 
Vitamins (see 2.4).  
 
2.5.3 Electrolytes 
 
The major electrolytes necessary for nutritional support are sodium, potassium, 
calcium, magnesium, chloride, acetate and phosphate. Daily requirements of each 
ion can vary widely and depending on the disease state. The major physical-
chemical incompatibility, causing precipitation, occurs when high concentrations of 
calcium and phosphate are mixed together. As the pH rises, more dibasic 
phosphate becomes available to react with calcium ions to form the precipitate. At 
low pH the monobasic ion predominates, being a far more soluble salt, 
precipitation is unlikely to occur. The most important factor influencing the 
maximum solubility of calcium + phosphate added to TPN mixtures is, therefore, 
pH. Practical considerations are also important. It is necessary to add and dilute 
the phosphate salt before adding calcium ions to maximize the solubility of the two 
ions of TPN mixtures. Other additives such as TE and vitamins appear to have no 
effect on the solubility of calcium phosphate2. 
 
 
2.5.4 Trace Elements (TE) 
 
TE addition may lead to numerous physical, chemical and nutritional interactions 
especially between vitamins and TE, or amino acids and TE. But the addition of 
some TE does not seem to alter the stability of a parenteral mixture22. TE, in 
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particular copper and iron, may interact with complete PN mixtures leading to 
precipitate formation. According to Allwood17 results, copper sulphide precipitated 
most rapidly in PN mixtures containing Vamin 9 ® and in mixtures stored in 
multilayered bags. Copper sulphide precipitation was delayed in PN mixtures 
containing Vamin 14 ® and was not observed in PN mixtures stored in EVA bags. 
Iron phosphate precipitates were observed in Synthamin®-containing PN mixtures 
after storage, but this was prevented in mixtures containing vitamins stored in 
multilayered bags. From this study result that stability of TE in TPN depends on 
source of amino acids and type of used container as well.  
 
There is an important interaction between selenium (Se) and vitamin C and E. Se 
is combined with both of them due to its anti-oxidative role. It protects the cells 
against oxygen radicals, especially on the lipoprotein membranes22. Harraki22 
reported that the absorption of Se was much decreased when sodium selenite and 
ascorbic acid were provided orally together.  
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CHAPTER THREE: EXPERIMENTAL PART 
 
3.1 INTRODUCTION 
 
This chapter describes materials used for tests, preparation of the samples and 
physical instruments used for physical analysis of the vitamins. Chemical assays 
of the vitamins and oxalic acid by High Performance Liquid Chromatography 
(HPLC), and statistical analysis are explained as well.  
 
 
3.2 MATERIALS 
 
Table 3.1: Used materials, Manufacturers and Expiry Dates 
 
Materials Manufacturer Expiry Date 
Intralipid® 20%, Emulsion 
for infusion 500ml 
Fresenius Kabi Limited, 
Runcorn, Cheshire, U.K. 
08/2009 
Vitlipid® N Adult, 
Concentrate for emulsion 
for infusion, 10 ml 
Fresenius Kabi Limited, 
Birchwood, Warrington, 
U.K. 
10/2008 
Solvitio® N, Powder for 
concentrate for solution for 
infusion 
Fresenius Kabi Limited, 
Runcorn, Cheshire, U.K. 
01/2009 
 
 
Intralipid 20%  
Purified soybean oil, Emulsion for infusion, intravenous use 
500 ml, 20% fat emulsion containing 4.2 MJ (1000 kcal) 
500 ml contains:  
Active ingredient: Purified soybean oil 100 g 
Inactive ingredients: Purified egg phospholipids 6.0 g, Glycerol anhydrous 11.0 g, 
Water for injections to 500 ml. 
Osmolality: 350 mosmol/kg water 
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Vitlipid N Adult 
Concentrate for emulsion for infusion 
10.0 ml contains:  
Active ingredients: Retinol (as palmitate) (Vitamin A) 990 g, Ergocalciferol 
(Vitamin D2) 5 g, d1-alpha-tocopherol (Vitamin E) 9.1 mg, Phytomenadione 
(Vitamin K) 150g 
Inactive ingredients: Fractionated soybean oil 1.0 g, Fractionated egg 
phospholipids 120 mg, Glycerol 225 mg, Sodium hydroxide q.s., Water for 
injection to 10.0 ml 
 
 
Solvitio N 
Powder for concentrate for solution for infusion 
1 vial contains 484 mg powder 
Active ingredients: Thiamine Nitrate 3.1 mg, Sodium riboflavine phosphate 4.9 mg, 
Nicotinamide 40 mg, Pyridoxine hydrochloride 4.9 mg, Sodium pantothenate 16.5 
mg, Sodium ascorbate 113 mg, Biotin 60 micrograms, Folic acid 0.4 mg, 
Cyanocobalamin 5.0 micrograms 
Inactive ingredients: Methyl parahydroxybenzoate 0.5 mg, Glycine 300 mg, 
Disodium edetate 0.5 mg 
These correspond to: Vitamin B1 2.5 mg, Vitamin B2 3.6 mg, Nicotinamide 40 mg, 
Vitamin B6 4.0 mg, Pantothenic acid 15.0 mg, Vitamin C 100mg, Biotin 60 g, Folic 
acid 0.4 mg, Vitamin B12  5.0 g 
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Table 3.2: Reagents and Suppliers 
 
Reagent Supplier 
Methanol (HPLC grade) Fisher Scientific U.K. 
Loughborough, Leicestershire 
Orthophosphoric acid 
(Analytical reagent grade) 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
diPotassium hydrogen 
orthophosphate trihydrate 
K2HPO4 . 3H2O 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
Barnstead Nanopure water Barnstead Thermolyne Corporation, 
Dubuque, Iowa 
pH 7 Buffer Fisher Scientific U.K. 
Loughborough, Leicestershire 
Potassium dihydrogen 
orthophosphate (HPLC grade) 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
L-Ascorbic acid 
(Analytical reagent grade) 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
Oxalic acid 
(Analytical reagent grade) 
Fisher Scientific U.K. 
Loughborough, Leicestershire 
 
 
Table 3.3: Sterile Equipment 
 
Sterile equipment Supplier 
BD Microlance 3 Needles 19G, 21G 
and 23G 
Becton Dickinson 
BD Plastipak 50 ml Luer-Lock 
Syringes 
Becton Dickinson 
BD Plastipak Syringes 1-20 ml Becton Dictinson 
Multi-Ad Luer-Lock Syringe Cap B/Braun 
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Table 3.4: Instruments 
 
Instruments Manufacturer 
HPLC system Thermo Spectrasystem 
Orion Model 420A 
pH/mV/Temperature Meter 
Beverly, MA, USA 
The Advanced Osmometer Model 
3D3 
Advanced Instruments, inc., 
Massachusetts, USA 
Weighing balance Sartorius Model 
A02 
Sartorius AG, Goettingen, Germany 
Microflow laminar flow cabinet, 
horizontal 
Bioquell UK Limited, Andover, Hants 
Pharmaceutical refrigerator Lec Refrigeration, Prescot, 
Merseyside 
Light microscope Olympus BH-2 Olympus Optical Co. Limited, Tokyo 
Autosampler 2.0 ml amber vials Fisher Scientific U.K. 
Loughborough, Leicestershire 
Disposable Pasteur pipettes, 3 ml Elkay Laboratory Products Ltd, 
Basingstoke, Hampshire 
Magnetic stirrer Fisher Scientific U.K. 
Loughborough, Leicestershire 
Micropipettes 100-1000L Gilson, France 
Malvern Mastersizer® X Malvern Instruments Limited, 
Worcestershire 
Thoma welled slides and cover slips Weber Scientific International Limited, 
Teddington, Middlesex 
Glassware Fisher Scientific U.K. 
Loughborough, Leicestershire 
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3.3 EXPERIMENTAL DESIGN 
 
3.3.1 The Preparation of Intralipid® 20% Syringes 
 
The Intralipid® 20% emulsion was placed into a laminar flow unit. 260 ml of this 
emulsion were syringed out and put into the sink. 240 ml of the emulsion remained 
in the bag. Then 10 ml of Vitlipid® N emulsion were put into a 10ml syringe and 
one vial of Solvitio® N was reconstituted by this emulsion. The created mixture 
was syringed via the same 10ml syringe into the Intralipid® emulsion. In all, there 
were 60 ml of Vitlipid®-Solvitio® mixture syringed into the Intralipid® emulsion. 
That means six vials of Solvitio N and six vials of Vitlipid N emulsion were 
used. Total volume of the Intralipid® mixture at this point was 300 ml. There were 
six 50ml Luer-Lock Syringes prepared in total. Each of them was filled with 47 ml 
of the Intralipid® mixture and closed by Multi-Ad Luer-Lock Syringe Cap. These 
syringes were placed into the refrigerator for stability tests to be carried out at a 
different time. The sample for chemical and physical assays at time zero was 
taken directly from the Intralipid® mixture and was taken into Hach tube. Two 
autosampler vials were filled via a 3ml plastic pipette for HPLC assay; each was 
filled with 1 ml of the sample.  Physical tests were carried out as well.   
 
Figure 3.1: Intralipid® Syringes 
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Figure 3.2: Hach tube  
               
 
3.3.2. Sampling technique of Intralipid® 20% Syringes 
 
Chemical assays by HPLC and physical tests were carried out after: 
 7 days storage in the refrigerator followed 24 h and 48 h storage at ambient 
temperature and protected from day-light. Two syringes were used and 
each day 15 ml of the volume was used for analysis. 
 14 days storage in the refrigerator followed 24 h and 48 h storage at 
ambient temperature and protected from day-light. Another two syringes 
were used and each day 15 ml of the volume was used for analysis. 
 29 days storage in the refrigerator followed 24 h and 48 h storage at 
ambient temperature and protected from day-light. The last two syringes 
were used and each day 15 ml of the volume was used for analysis. 
 
3.3.3 Sampling Technique of AA and OA Analysis 
 
Three different samples were prepared. Firstly 100 mg AA reconstituted with 
UFDW in 100ml volumetric flask and diluted 30 times into 10ml volumetric flask. 
Secondly 100 mg OA filled with UFDW in a 100ml volumetric flask and diluted 30 
times in 10ml volumetric flask. The third sample was prepared by mixing 100 mg 
AA with 100 mg OA, dissolving in a 100 ml volumetric flask in UFDW and solution 
prepared this way was diluted 30 times in a 10ml volumetric flask. Each sample 
was assayed by HPLC in time zero and after 1, 4, 5, 6 and 7 days storage at 
ambient temperature. The solutions were not protected against daylight.  
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3.4 PHYSICAL ANALYSIS 
 
The following analyses were carried out. Emulsions were visually checked with the 
naked eye as well as by light microscopy. The lipid particle size was measured by 
Malvern Mastersizer® X, and the osmolality was measured with The Advanced 
Osmometer. The pH of the emulsions was determined by using Orion pH meter. 
 
  
3.5 INSTRUMENTS USED FOR PHYSICAL TESTS 
 
Instruments which were used are listed in Table 3.4. 
 
3.5.1 Light Microscope 
 
Microscopy was used for observation of lipid particle size in tested emulsion 
samples. A pre-calibrated light microscope (Olympus® BH–2) was used. 
 
Figure 3.3: Olympus® BH-2 
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One drop of the emulsion was placed in the centre of a Thoma-welled counting 
chamber slide of a height of 0.2 mm, and gridlines of a total of 256 squares. A 1ml 
syringe was used and the sample was then covered with a glass cover slip. It is 
important to avoid creating air bubbles, which may cause a problem, because their 
appearance is similar to lipid globules.  
The samples were examined at 100-time magnification. One unit gridline of the 
scale is equivalent to 10 m in size. The biggest particle size, the amount of 
particles bigger than 10 m and particles between 7.5-10 m, were recorded. The 
particles that were visible outside of the grid were not included. 
 
3.5.2 The Mastersizer® X Laser Diffraction Particle Size Analyser 
 
The Malvern Mastersizer particle size analyzer uses the laser diffraction 
technique which is based on the analysis of the diffraction pattern produced when 
particles are exposed to a beam of monochromatic light. 
 
 
Figure 3.4: Laser diffraction system 
 
 
 A representative sample, dispersed at an adequate concentration in a suitable 
liquid or gas, is passed through a beam of monochromatic light, usually a laser. 
The light scattered by the particles at various angles is measured by a multi-
element detector. Numerical values representing the scattering pattern are then 
recorded for subsequent analysis. These scattering pattern values are then 
transformed, using an appropriate optical model and mathematical procedure, to 
yield the proportion of total volume to a discrete number of size classes, forming a 
volumetric particle-size distribution.  
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Figure 3.5: Laser diffraction instrument 
 
 
 
 
 
The particles can enter the laser beam in 2 positions. In the conventional case the 
particles enter the parallel beam before the collecting lens and within its working 
distance. In so-called reversed Fourier optics the particles enter behind the 
collecting lens and thus, in a converging beam. The advantage of the conventional 
set-up is that a reasonable path length for the sample is allowed within the working 
distance of the lens. The second set-up allows only small path lengths but enables 
measurement of scattered light at larger angles, which is useful when submicron 
particles are present. Traditionally, the measurement of particle size using laser 
diffraction has been limited to particles in the range of approximately 0.1 µm to 
3 mm (British Pharmacopoeia 2008)23. 
 
The size of the lipid globules is measured by passing the laser beam through the 
emulsion samples dispersed in ultrapure deionised water. The sampler was filled 
with ultrapure deionised water and stirred at a constant flow rate. Firstly the 
background was measured and then the sample was added. It was necessary to 
add the sample slowly. The amount of sample required was adjusted to an 
obscuration value between 19% - 21%. Initial tests carried out with Intralipid® 
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emulsions required to add about 3 drops of this emulsion to obtain this obscuration 
concentration. The particle size data was analysed using the Malvern 
Mastersizer® software version 2.19. 
 
3.5.3 The pH Meter 
 
The pH is a number which represents conventionally the hydrogen ion 
concentration of an aqueous solution (BP 2008)24. Orion® Model 420A pH meter 
was used for measuring my samples. This measuring system comprises of two 
electrodes, the sensitive glass electrode and a combined reference electrode.  
 
 
Figure 3.6: Orion® pH meter Model 420A 
 
 
 
 
The glass electrode consists of a glass tube with a sealed membrane of glass at 
its base. The membrane glass bulb is filled with buffer into which a silver wire (Ag) 
coated with silver chloride (AgCl) is placed (A Guide to Electrochemistry). When a 
pH glass electrode comes in contact with an aqueous measuring solution a gel 
layer develops on the pH-sensitive glass membrane and inside of this membrane 
as well. The H ions either diffuse out of the layer or into the gel layer, depending 
on the pH value of the measured solution. The total membrane potential is a result 
of the difference between the inner and outer charge. In the combination electrode 
the glass electrode is concentrically surrounded by the reference electrolyte25. 
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The pH meter was calibrated before use with pH 7 phosphate buffer (Fisher 
Scientific U.K., Loughborough, Leicestershire). The glass electrode was inserted 
into the sample using the holder. It is necessary to wash the glass electrode with 
distilled water between measuring each sample to prevent contamination.  
 
 
3.5.4 Osmometer 
 
Osmometers are devices designed for extremely precise measurement of the 
osmotic concentration of body fluids. The Advanced Model 3D3 Osmometer 
determines solute concentration by the extremely precise freezing point method 
(User’s Guide, Advanced Instruments 1996). 
 
Osmometer is the apparatus for measuring osmolality. The unit of osmolality is 
osmole per kilogram (osmol/kg), but the submultiple milliosmole per kilogram 
(mosmol/kg) is usually used. Osmolality m is determined by measurement of the 
depression of freezing point. The following relationship exists between the 
osmolality and the depression of freezing point ΔT (BP 2008)26:  
 
m = kgmosmol
T /1000
86.1
  
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Figure 3.7: The Advanced Osmometer 
 
 
 
A pre-calibrated The Advanced Osmometer Model 3D3 was used.  The amount 
of 250 l of the sample was given into sample tubes for in vitro diagnostic with 
Gilson micropipette. Osmolality was determined at each sample at time zero, after 
29 days of storage in the refrigerator followed by 24 hours and 48 hours of storage 
at ambient temperature and under light protected conditions. 
 
3.5.5 Laminar Flow Cabinet 
 
The horizontal laminar flow cabinet, Microflow, is fitted with high efficiency 
particulate air (HEPA) filter with 99.97% efficiency. The HEPA filter provides ultra-
filtered air and allows a clean air work environment (Said 2006b)27. 
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Figure 3.8: Laminar flow workstation 
 
 
 
 
 
 
3.6 CHEMICAL ASSAYS BY HPLC 
 
HPLC is becoming a standard method in vitamin assay, especially for routine 
work28. Liquid chromatography (LC) is a method of chromatographic separation 
based on the difference in the distribution of species between two non-miscible 
phases, in which the mobile phase is a liquid which percolates through a stationary 
phase contained in a column. The apparatus consists of a pumping system, an 
injector, a chromatographic column, a detector and a data acquisition system. The 
mobile phase is supplied from one or several reservoirs and flows through the 
column, usually at a constant rate, and then through the detector29.  
 
3.6.1 HPLC Instrument System Used for Analysis of Intralipid® Syringes 
  
Thermo Spectra System P2000 gradient pump, UV detector 6000LP and Spectra 
Series AS1000 autosampler with 20l injection loop were used for the HPLC 
analysis. The data acquisition system software was called Chromquest 4.1. The 
column used was Varian® C18 stainless steel column, 150 mm × 3 mm ID, 5 µm 
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particle size, fitted with a ChromStep C18 stainless steel guard column, 10 mm  
2 mm ID.   
 
3.6.2 HPLC Analysis of Water-soluble Vitamins Assay 
 
Solvitio® N Adult is an injectable multivitamin, in the form of a yellow powder for 
reconstitution (Said 2006b) 27. 
 
The separation method from Khýnová30 was adapted for the water-soluble 
vitamins. All samples were analysed at ambient temperature, a reversed phase 
HPLC analysis with a gradient elution method was employed. Methanol and 
phosphate buffer 0.05M pH 7 was used as the mobile phase. The following 
gradient run was used:  
 1% methanol from 0 to 5 minutes, 
 1% - 30% methanol from 5 to15 minutes, 
 30% methanol from 15 to 20 minutes, 
 30% - 1% methanol from 20 to 20.1 minutes, 
 1% methanol from 20.1 to 25 minutes 
 
Table 3.5: Gradient Run for Water-soluble Vitamins Assays 
 
Time (minutes) Buffer pH 7 MeOH 
 A% B% 
0 99 1 
5 99 1 
15 70 30 
20 70 30 
20.1 99 1 
25 99 1 
 
20 l sample was injected via autosampler. The flow rate was set 1 ml/min with UV 
detection 265 nm. 
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3.6.2.1 Preparation of Phosphate Buffer for Intralipid® Syringes Analysis 
 
The mobile phase used consists of phosphate buffer and methanol. Fresh solution 
of 0.05M phosphate buffer pH 7 was prepared by dissolving 11.41 g 0.05M 
K2HPO4.3H2O in ultrafiltered deionised water (UDW). This solution was put into a 
1000ml volumetric flask and filled with UDW. Amount of weighed K2HPO4.3H2O 
(formula mass FM= 228.22) was counted via the following figure: 0.05M  228.22 
= 11.41 g ( 0.05 g). The solution was put in a beaker, stirred with a magnetic 
stirrer and pH of this solution was measured. pH was adjusted to pH 7  0.05 units 
by using orthophosphoric acid. Finally the buffer was filtered under vacuum 
through a 0.2 m polyamide filter. 
 
  
3.6.3 HPLC Analysis of Fat-soluble Vitamins Assay 
 
For the fat-soluble vitamins, the UV absorbance found was 292 nm for vitamin E 
and 325 nm for vitamin A. Therefore methods that use two different wavelengths 
were carried out (Said 2006b)27. According to Said 2006 results, using the stability-
indicating method described helps determine two vitamins, namely Vitamin A and 
Vitamin E. The other fat-soluble vitamins were omitted in this thesis. Methanol was 
used as the mobile phase.  
 
A reversed phase HPLC analysis using two different UV detections in a single run 
was employed. The mobile phase was methanol HPLC grade, set at a flow rate of 
1.5 ml/min. Two wavelengths were used, 292 nm for the detection of vitamin E and 
325 nm for the detection of vitamin A. A 20 µl sample was injected via the 
autosampler. 
 
3.6.4 HPLC Instrument System Used for AA and OA Analysis 
 
Thermo Spectra System P2000 gradient pump, UV detector 6000LP and Spectra 
Series AS1000 autosampler with 20l injection loop were used for the HPLC 
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analysis. The data acquisition system software was called Chromquest 4.1. The 
column used was Synergi 4  Hydro-RP 80A, 250 x 4.60 mm, Phenomenex.  
 
3.6.4.1 Preparation of Phosphate Buffer for AA and OA Analysis 
 
The mobile phase used was 0.02M phosphate buffer pH 2.5. The fresh buffer was 
prepared by dissolving 2.72 g KH2PO4 in UDW. The amount of weighed KH2PO4 
(formula mass FM= 136.086) was counted via the following figure: 0.02M  
136.086= 2.72 g ( 0.05 g). This solution was put into a 1000ml volumetric flask 
and filled with UDW, and after mixing was put into a beaker with magnetic stirrer. 
The pH of the solution was adjusted with orthophosphoric acid to pH 2.5  0.05 
units. Finally the buffer was filtered under vacuum through a 0.2 m polyamide 
filter.  
 
3.7 STATISTICAL ANALYSIS 
 
Microsoft Excel 2003 software for Windows was used for data analysis. All 
results throughout the project were expressed as the mean  standard deviation 
(SD) from triplicate samples.  
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CHAPTER FOUR: RESULTS AND DISCUSSION 
 
4.1 HPLC ANALYSIS OF INTRALIPID® SYRINGES 
 
Firstly it was necessary to find an optimal method for vitamin assay by HPLC. The 
initial step was reading the diploma thesis of mine, Khýnová30, paragraph 4.1: 
HPLC Analysis of Kabiven® Peripheral Bag. Mentioned project was similar to the 
one discussed in this rigorous thesis. Literature about vitamin assays by HPLC 
was consulted as well (For example PhD thesis of Said).  
 
The separation method from Khýnová30 was adapted for the water-soluble and the 
fat-soluble vitamins analysis. The same column and HPLC system, like Khýnová30 
used, was employed. 
 
4.1.1 Results and Discussion for Water-soluble Vitamins 
  
The chromatogram of Solvitio N standard solution is shown at Figure 4.1. Peaks 
of the Solvitio N solution were identified according to Khýnová30 results. 
 
Figure 4.1: Chromatogram of Solvitio N Standard Solution 
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The chromatogram peaks with the approximate retention times were:  
Ascorbic acid rt. 0.67 minutes 
Pyridoxine hydrochloride rt. 3.46 minutes   
Nicotinamide rt. 4.82 minutes 
Thiamine hydrochloride rt. 5.54 minutes 
Folic acid rt. 10.23 minutes 
Riboflavin sodium phosphate rt. 14.61 minutes 
Pantothenic acid rt. 19.09 minutes 
 
 
Five peaks for riboflavin sodium phosphate were identified according to Said’s 
2006 results, which may be the isomers of riboflavin phosphate, riboflavin 
diphosphate and free riboflavin. The highest peak identified at about 14.61 
minutes was used for analysis. Ascorbic acid was eluted very early in the gradient 
run, in less than one minute. The peak for cyanocobalamin was also identified, but 
its concentration in the multivitamin solution was too minute and the peak was 
hardly noticeable. The biotin peak could not be identified in this gradient run, and 
the peak for pantothenic acid was detected after 20 minutes of the gradient run. In 
Said’s 2006 thesis the peaks of degraded products were identified, mostly at 
retention times of less than 2 minutes. Therefore it was decided that this method 
was not suitable for analysing the ascorbic acid, because the peaks of the 
degraded products would interfere with the ascorbic acid peak.  
Six vitamins were found to be suitable for assay by this method, which are 
pyridoxine, nicotinamide, thiamine, folic acid, riboflavin sodium phosphate and 
pantothenic acid (Said 2006b)27. All these vitamins were analysed in different 
times in Intralipid® syringes (Figure 4.2). 
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Figure 4.2: Chromatogram of Intralipid Syringe – Detection of Water-soluble 
Vitamins. Separation of Pyridoxine (rt. 4.05 minutes), NA (rt. 5.46 minutes), 
Thiamine (rt. 6.62 minutes), FA (rt. 10.50 minutes), Riboflavin sodium phosphate 
(rt. 14.94 minutes), PA (rt. 20.22 minutes). 
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4.1.1.1 Results of HPLC for Water-soluble Vitamins (WSV) in Intralipid® Syringes 
 
Amount of vitamin B6 was not less than 94 % during the storage period. Almost 
100 % of the vitamin left after 7 days and 14 days storage in the refrigerator 
followed two days storage at ambient temperature. There was detected over 94 % 
of the vitamin at the day 29+2 (see Table 4.1).  
 
Amount of Nicotinic acid (NA) was not less than 85 % of its initial amount during 
storage period. Around 86 % of the vitamin left after 7 days storage in the fridge 
followed two days storage at ambient temperature. Over 99 % of NA left after 14 
days storage, but during two days storage at ambient temperature amount of NA 
decreased to 89 % of its initial amount. Similar amount of this vitamin like at the 
day 14 was detected at the day 29. Over 85 % of NA was presented at the day 
29+2 in the sample (see Table 4.1).  
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Amount of vitamin B1 was not less than 94 % during storage period. Almost 100 % 
of the vitamin was presented after 7 days storage in the fridge. During storage at 
ambient temperature the amount of vitamin B1 was decreasing. Losses of the 
vitamin were small after 14 and 29 days storage, around 3 % (see Table 4.1).  
 
Amount of Folic acid (FA) was not less than 68 % of its initial amount during 
storage period. There was detected only 84 % of FA at the day 7, 82 % at the day 
14 and 94 % at the day 29. Amount of this vitamin after two days storage at 
ambient temperature was decreasing at all time points (see Table 4.1).  
 
Amount of vitamin B2 was not less than 63 % during storage period. Around 63 % 
of the vitamin left after 7 days storage in the fridge followed two days storage at 
ambient temperature. There was detected around 76 % of vitamin B2 at the day 
14 and only 65 % of the vitamin at the day 29+2.  
 
Amount of Pantothenic acid (PA) was not less than 82 % of its initial amount 
during storage period. Almost 90 % of PA left after 7 days storage. There was 
detected around 96 % of this vitamin after 14 days storage and almost 83 % at the 
day 29 (see Table 4.1). 
 
There were detected also values over 100 % of the initial amount of the vitamins. It 
might be caused by measure error. Some results may be influenced by changing 
ambient temperature during stability studies, because the room where HPLC 
system was, was not equipped by air-condition. Exactly the sensitivity of the 
detector may be influenced by big temperature difference between single assays 
and column could be influenced as well.  
 
All results are expressed via graphs (see Figures 4.3, 4.4 and 4.5) and Table 4.1.   
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Table 4.1: Peak Area and RSD for WSV in Intralipid® Syringes throughout the 
Investigation 
 
Vitamin B6  NA  B1  FA  B2  PA  
Day % RSD % RSD % RSD % RSD % RSD % RSD 
0 100 0,30 100 1,40 100 0,19 100 1,39 100 1,42 100 4,55 
7 101,7 0,47 87,0 1,28 99,4 4,40 84,8 5,18 63,3 3,94 89,7 1,08 
7+1 101,4 4,24 86,6 1,21 95,7 3,29 110,5 4,48 91,4 8,49 97,3 2,80 
7+2 99,9 1,26 98,3 1,78 94,9 5,19 73,4 3,71 65,7 5,43 96,6 1,33 
                          
 B6  NA  B1  FA  B2  PA  
Day % RSD % RSD % RSD % RSD % RSD % RSD 
0 100 0,30 100 1,40 100 0,19 100 1,39 100 1,42 100 4,55 
14 101,6 0,64 99,2 2,09 96,5 4,07 82,5 5,17 76,6 3,81 96,1 1,22 
14+1 100,4 0,37 92,3 2,08 100,7 3,58 79,2 5,85 71,1 2,37 97,9 1,92 
14+2 96,8 0,80 89,7 2,34 100,3 5,23 74,4 6,09 68,1 2,69 100,7 1,95 
                          
 B6  NA  B1  FA  B2  PA  
Day % RSD % RSD % RSD % RSD % RSD % RSD 
0 100 0,30 100 1,40 100 0,19 100 1,39 100 1,42 100 4,55 
29 104,9 0,63 99,6 1,83 98,8 4,65 94,4 4,81 98,2 9,78 82,9 4,41 
29+1 98,9 0,82 94,3 2,06 102,7 4,07 76,6 4,96 81,1 11,2 92,6 1,23 
29+2 94,5 1,28 85,4 1,99 103,5 3,29 68,2 5,23 65,3 7,04 98,7 0,85 
 
 
Figure 4.3: Peak Area for WSV in the Syringes after 7 Days Storage in the Fridge 
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Figure 4.4: Peak Area for WSV in the Syringes after 14 Days Storage in the Fridge 
 
 
Figure 4.5: Peak Area for WSV in Syringes after 29 Days Storage in the Fridge 
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4.1.1.2 Discussion  
 
Stability of vitamins is discussed in previous paragraph 2.4 Vitamins. Pyridoxine is 
light-sensitive vitamin and its losses were reported more than 80 % when exposed 
to daylight2. Previous HPLC results have shown that degradation of pyridoxine is 
negligible when the samples are light protected. Pyridoxine was shown as a stable 
vitamin because its losses were small during whole storage period. HPLC results 
of NA have shown that its losses during storage in the fridge were small. More 
significant degradation of NA was noticed after two days storage at ambient 
temperature. Therefore samples containing NA should be stored in a refrigerator 
before administration to patients. Thiamine was shown to be stable in the mixture 
with fat emulsion. Almost no losses were detected when thiamine containing 
samples were stored in the fridge. Previous HPLC results have shown that FA was 
rapidly degraded when the samples were stored out of the fridge. Losses of FA in 
the mixture with fat emulsion were less if the samples stored in the fridge, around 
17 % of its initial amount. FA degradation is rapid so mixtures containing FA 
should be administered to patients after preparation and not stored. Riboflavin 
losses were significant throughout investigation, especially when samples were 
stored at ambient temperature for two days. Riboflavin containing mixtures should 
be administered after preparation as well as mixtures with FA. Previous HPLC 
results have shown that PA degradation is small even after long time storage 
period. Losses of this vitamin were negligible if samples stored in the fridge as well 
as at ambient temperature.   
 
4.1.2 Results and Discussion for Fat-soluble Vitamins Assay 
 
Peaks for vitamin A and vitamin E were identified by comparing chromatograms of 
fat-soluble sample emulsion from Said 2006 thesis with chromatograms obtained 
from analysis of 10 ml of Vitlipid® N Adult injection diluted in a 100ml volumetric 
flask with ultrafiltered deionised water. Peaks were identified at 2.65 minutes for 
vitamin E (Figure 3.14) and at 8.53 minutes for vitamin A (Figure 3.15).  Peaks for 
vitamin K and vitamin D were observed too, but according to Said 2006 results 
these two vitamins are unsuitable for analysis by this stability-indicating method. 
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Vitamin K peak was too small with lack of sensitivity and from the calibration curve 
of vitamin D less linearity and therefore less precision was found. 
For the fat-soluble Vitlipid N Adult vitamin assay the stability-indicating method 
described was able to determine two vitamins, namely Vitamin A and Vitamin E in 
single run27.  
 
Figure 4.6: Chromatogram of Vitlipid N Injection - Detection of Vitamin E (rt. 2.65 
minutes) 
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Figure 4.7: Chromatogram of Vitlipid N Injection- Detection of Vitamin A (rt. 8.53 
minutes) 
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Figure 4.8: Chromatogram of Intralipid Syringe – Detection of Vitamin E (rt. 2.44 
minutes) 
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Figure 4.9: Chromatogram of Intralipid Syringe- Detection of Vitamin A (rt. 9.58) 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
m
A
U
0
100
200
300
1
5
6
8
0
0
6
9
  
9
.5
8
0
1
1
2
0
2
2
  
1
2
.3
0
2
UV6000-325nm
A02
Area
Retention Time
 
 
4.1.2.1 Results of HPLC for Fat-soluble Vitamins (FSV) in Intralipid® Syringes 
 
Amount of vitamin A was not less than 79 % of its initial amount during storage 
period. There was detected around 95 % of the vitamin after 7 days storage in the 
fridge followed two days storage at ambient temperature. At the day 14 there was 
presented almost 94 % of vitamin A in the sample and almost 80 % of the vitamin 
was detected at the day 29 (see table 4.2). Amount of vitamin E was not less than 
76 % during storage period. This value was detected after 29 days storage in the 
refrigerator. Amount of vitamin E at the day 7 and 14 was around 90 % of i ts initial 
amount (see table 4.2).  
 
There were detected values over 100 % of initial amount of the vitamins. Some 
results may be influenced by changing ambient temperature during stability 
studies, because the room where HPLC system was, was not equipped by air-
condition. Exactly the sensitivity of the detector may be influenced by big 
temperature difference between single assays and column could be influenced as 
well.  
 
All results are expressed via graphs (see Figures 4.10, 4.11 and 4.12) and Table 
4.2. 
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Table 4.2: Peak Area and RSD of FSV in the Syringes throughout the Investigation 
 
 Vitamin A   E   
Day Peak Area (%) RSD Peak Area (%) RSD 
0 100 0,19 100 2,43 
7 93,8 0,79 89,5 1,23 
7+1 98,2 0,74 92,5 1,45 
7+2 95,9 2,39 105,4 1,08 
          
  A   E   
Day Peak Area (%) RSD Peak Area (%) RSD 
0 100 0,19 100 2,43 
14 93,7 0,43 91,3 2,10 
14+1 96,4 2,08 97,1 1,80 
14+2 107,2 0,19 101,5 0,52 
          
  A   E   
Day Peak Area (%) RSD Peak Area (%) RSD 
0 100 0,19 100 2,43 
29 79,8 0,11 76,3 0,93 
29+1 94,6 3,12 96,1 1,12 
29+2 121,7 0,11 114,9 0,37 
 
 
Figure 4.10: Peak Area for FSV in the Syringes after 7 Days Storage in the Fridge 
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Figure 4.11: Peak Area for FSV in the Syringes after 14 Days Storage in the 
Fridge 
 
 
 
 
Figure 4.12: Peak Area for FSV in the Syringes after 29 days Storage in the Fridge 
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4.1.2.2 Discussion 
 
Stability of vitamins A and E was discussed in previous paragraph 2.4. Vitamins. 
Retinol is the most light-sensitive of the vitamins and is known to be rapidly broken 
down by exposure to UV light2. Intralipid® Syringes were daylight-protected 
throughout the investigation, therefore degradation was not rapid. Vitamin A in the 
mixture with fat emulsion was shown quite stable if its samples stored in the fridge. 
An influence of the temperature was not possible to evaluate beacause the peak 
area values after storage at ambient temperature were inapplicable. Gillis19 
reported that vitamin E may be strongly bound to plastic. According to previous 
results vitamin E losses were not rapid in the mixture with fat emulsion. Allwood2 
reported that presecne of a fat emulsion affords considerable protection.  
 
4.2 RESULTS AND DISCUSSION OF pH FOR INTRALIPID® SYRINGES 
 
4.2.1 pH Results of Intralipid® Syringes 
 
The measured pH was in range between 6.16 at day zero and 6.61 at day seven. 
There is not any difference bigger than 0.5 units among all results. The biggest 
difference is between day zero and day seven, exactly 0.45 units (see Table 4.3). 
The changes of pH after 24 and 48 hours storage at ambient temperature are 
quite small and do not differ from the day when they were take out from the fridge 
to much. The biggest difference is between day seven and seven plus two, exactly 
0.24 units. The graphical results are expressed in Figures 4.13, 4.14 and 4.15 in 
differen time. 
 
Table 4.3: pH of Intralipid® Syringes throughout The Investigation 
 
day 0 7 7+1 7+2 14 14+1 14+2 29 29+1 29+2 
pH 6.16 6.61 6.48 6.37 6.55 6.45 6.45 6.40 6.31 6.34 
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Figure 4.13: pH of The Syringes after 7 Days Storage in The Fridge 
 
 
 
 
Figure 4.14: pH of The Syringes after 14 Days Storage in The Fridge 
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Figure 4.15: pH of The Syringes after 29 Days Storage in The Fridge 
 
 
4.2.2 Discussion  
Allwood2 has reported that pH changes can lead to significant loss of stability or to 
precipitation. That is the reason why observation of pH is very important. Changes 
of pH which are less than 0.5 units are negligible. Only changes of pH bigger than 
0.5 units may cause dangerous precipitation. According to the results all pH  
changes were in norm. The biggest difference in pH values was between initial pH 
value and the pH values after longer storage period in the fridge (7, 14 and 29 
days). Storage of syringes at ambient temperature was not manifest any 
significant pH changes. Therefore, investigated admixtures were suitable for 
intravenous delivery.  
 
4.3 RESULTS AND DISCUSSION OF INTRALIPID® SYRINGES MICROSCOPY 
 
4.3.1 Microscopy Results of Intralipid® Syringes 
 
Many enlarged lipid particles were seen in Intralipid® admixtures. The biggest one 
of 15 µm was observed at day twenty nine plus one (see Table 4.4). One particle 
bigger than 10 µm was observed at day seven plus one, seven plus two, fourteen 
plus two and twenty-nine plus one. Four particles bigger than 10 µm were 
observed at day fourteen plus one. Particles in range 7.5 and 10 µm are showed in 
Table 4.5. All other lipid globules were 5µm or smaller at all time points.   
 
 
69 
 
 
Table 4.4: Results of Microscopy of Intralipid® Syringes 
 
Intralipid® 
Syringes       
Day 
Biggest Particle Size 
(m) 
Amount of Particles 
10m
Particles Between 
7.5-10 m 
0 10 0 3 
     
7 10 0 3 
     
7+1 12,5 1 2 
     
7+2 12,5 1 3 
     
14 10 0 3 
     
14+1 12,5 4 4 
     
14+2 12,5 1 3 
     
29 10 0 2 
     
29+1 15 1 4 
     
29+2 10 0 4 
 
 
 
4.3.2 Discussion 
 
Potential interactions of combined TPN mixtures were discussed in paragraph 2.5. 
Allwood2 reported that precipitation may be a result of temperature changes, pH 
changes or poor mixing. The results have showed that the most stable admixtures 
are those stored in refrigerator. If they are stored out of refrigerator they become 
unstable because of higher amount of enlarged lipid globules. Higher amount of 
lipid particles is presented when investigated admixtures are stored for period 
longer than 7 days. It means that stability of discussed admixtures is decreasing 
when storage period is prolonged and admixtures are stored at ambient 
temperature.  
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4.4 RESULTS AND DISCUSSION OF LASER DIFFRACTION OF INTRALIPID® 
SYRINGES 
 
4.4.1 Intralipid® Syringes Laser Diffraction Results 
 
No lipid droplets greater than 5.29 µm were detected in any Syringes (see Figures 
4.16 and 4.17). Many samples presented a maximum particle size of just 3.49 µm.  
 
 
Figure 4.16: Particle Size Distribution of Globules in Lipid Admixtures (Syringes-
Day Zero) 
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Figure 4.17: Particle Size Distribution of Globules in Lipid Admixtures (Syringes-
Day twenty-nine) 
 
 
 
 
4.4.2 Discussion 
 
Intravenously administered fat droplets exceeding 5 µm in diameter are believed to 
cause adverse reactions, in particular emboli of the lungs. There was found a 
relationship between particle size and toxicity. The toxicity increases with higher 
average particle size and wider particle size distribution. Many autors take 5 µm as 
the upper limit, since larger particles pose a risck of lung embolism31. 
 
According to the results no lipid droplets in Intralipid® Syringes samples were 
enlarged. Emulsions in which > 0.4 % of the fat particles are above 5 µm, are likely 
to become unstable31. In discussed trials the volume of droplets bigger than 5 µm 
was 0 %. Concerning the lipid globules size this Intralipid® admixture could be 
used for intravenou delivery during  whole storage period. 
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4.5 RESULTS AND DISCUSSION OF OSMOLALITY OF INTRALIPID® 
SYRINGES 
 
Osmolality was measured at day zero, day twenty-nine, day twenty-nine plus one 
and day twenty-nine plus two. The values are expressed in Table 4.5. 
 
Table 4.5: Osmolality of The Syringes  
 
Day Osmolality (mOsm/kg) 
0 469 
29 467 
29+1 475 
29+2 472 
 
There was not noticed any significant difference among osmolality results during 
storage period.  
 
4.6 HPLC ANALYSIS OF OXALIC ACID AND ASCORBIC ACID 
 
4.6.1 Determination of Optimal HPLC Method 
 
Firstly it was necessary to develop an optimal method of analysing OA as 
degradation product of AA. Previously published literature about HPLC analysis of 
OA was consulted, the sources deal with the HPLC method for analysing organic 
acids (Tormo and Izco 2004)32, as well as the analysis of L-AA by HPLC 
(Novakova et al. 200833; Burini 200734) were red. 
 
 A special HPLC column for analysing polar compounds Synergi 4  Hydro-RP 
80A, 250 x 4.60 mm, Phenomenex was recommended and employed. Information 
about this column and the method convenient for analysing OA was retrieved from 
the Phenomenex 05/06 Catalog. This column can provide improved retention of 
extremely polar compounds when 100% aqueous mobile phase on C18 column is 
used. Separation method recommended for OA analysis by this column was 
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investigated. 20mM Potassium phosphate pH 2.9 as a mobile phase was 
employed, flow rate was set up to 0.7 mL/min and UV detection used was 220 nm. 
Obtained chromatograms showed suitable separation of AA and OA, but OA peak 
was not sharp enough, so the used method was slightly changed. Flow rate was 
changed to 1 mL/min and pH of mobile phase was adjusted to pH 2.5  0.05 units. 
This alternative method appeared to be optimal and was used for further analysis. 
As storage solvent for the column was used 65 % acetonitrile and 35 % water 
solution, because the column must not be stored with buffers.  
 
4.6.2 HPLC Method Used 
 
All samples were analysed at ambient temperature, a reversed phase HPLC 
analysis was employed. As the mobile phase was used phosphate buffer 20mM 
pH 2.5. 20 l of the sample was injected via autosampler. The flow rate was set 1 
ml/min with UV detection 220 nm. 
 
4.6.3 Calibration Curves of AA and OA Making 
 
Two solutions were prepared. 100 mg AA was resolved in ultrafiltered deionised 
water (UDW), put into 100ml volumetric flask and filled with UDW, 100 mg OA was 
prepared employing the same technique like AA solution in a 100ml volumetric 
flask. Both of these solutions were diluted 14.5 times and 30 times into a 10ml 
volumetric flask, and were analysed. 30 times dilution was suitable for making a 
calibration curve (see Figure 4.20), whereas 14.5 times dilution seemed to be 
much concentrated. The sample solution with 100 mg AA and 100 mg OA 
resolved with UDW in 100ml volumetric flask was prepared. Then the sample 
solution was diluted 30 times with UDW and used for calibration curve making 
(see figure 4.21) The calibration curve of AA and OA (see Figures 4.18 and 4.19) 
was determined by analysing five different concentrations at the concentration 
range between 50% - 125% of the sample solution in triplicate, namely 50, 75, 90, 
100 and 125%. The calibration curves were constructed by plotting peak area 
versus concentration. The correlation coefficients (R2) and relative standard 
deviations (RSD) were established.  
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Table 4.6: Correlation Coefficients (R2) and Average Relative Standard Deviations 
(RSD) of AA and OA Samples 
 
 
Vitamin RSD R2 
Ascorbic 
Acid 0.1531 0.9994 
Oxalic Acid 0.4004 0.9990 
 
 
 
Table 4.7: Average Peak Areas and Relative Standard Deviations (RSD) of AA 
and OA Sample Solutions 
 
 
 OA  AA  
Concentration 
Peak Area 
(%) RSD 
Peak Area 
(%) RSD 
50% 51.18 0.8547 50.51 0.2379 
75% 75.61 0.0764 74.33 0.2005 
90% 88.13 0.4607 88.49 0.1306 
100% 100.00 0.3791 100.00 0.1484 
125% 123.00 0.2311 123.33 0.0481 
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Figure 4.18: Calibration Curve of Ascorbic Acid 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 4.19: Calibration Curve of Oxalic Acid 
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Figure 4.20: Chromatogram of OA Solution (rt. 2.64 minutes) 
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Figure 4.21: Chromatogram of AA + OA Sample Solution (OA rt. 2.70 minutes, AA 
rt. 5.22 minutes) 
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4.6.4 Ascorbic Acid Degradation Results 
 
It was not possible to finish the AA degradation investigation because of the 
conclusion of my research fellowship. Stability studies of AA and OA degradation 
were not complete by the time I have left, therefore it was not possible to publish 
them in this thesis.  
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CHAPTER FIVE: CONCLUSIONS 
 
Stability of vitamins is discussed in previous paragraph 2.4 Vitamins. Almost all 
vitamins are light-sensitive and are known to be rapidly broken down by exposure 
to UV light2. Intralipid® Syringes were daylight-protected throughout the 
investigation, therefore degradation was not rapid. According to the Laser 
diffraction results no lipid droplets in Intralipid® Syringes samples were enlarged. 
Emulsions in which > 0.4 % of the fat particles are above 5 µm, are likely to 
become unstable40. In discussed trials the volume of droplets bigger than 5 µm 
was 0 %. Concerning the lipid globules size this Intralipid® admixture could be 
used for intravenou delivery during  whole storage period. Vitamin A in the mixture 
with fat emulsion was shown quite stable if its samples stored in the fridge. Gillis19 
reported that vitamin E may be strongly bound to plastics, especially to PVC. 
According to previous results vitamin E losses were not rapid in the mixture with 
fat emulsion. One of the reasons could be that Syringes used for storage of the 
mixtures are made from polypropylene/polyethylene and are PVC free. Allwood2 
reported that presence of a fat emulsion affords considerable protection. Previous 
HPLC results have shown that degradation of pyridoxine is negligible when the 
samples are light-protected. Pyridoxine was shown as a stable vitamin, because 
its losses were small during whole storage period. NA HPLC results have shown 
that its losses during storage in the fridge were small. More significant degradation 
of NA was noticed after two days storage at ambient temperature. Therefore 
samples containing NA should be stored in a refrigerator before administration to 
patients. Thiamine was shown to be stable in the mixture with fat emulsion. Almost 
no losses were detected when thiamine containing samples were stored in the 
fridge. Previous HPLC results have shown that FA was rapidly degraded when the 
samples were stored out of the fridge. Losses of FA in the mixture with fat 
emulsion were less if the samples stored in the fridge, around 17 % of its initial 
amount. FA degradation is rapid so mixtures containing FA should be 
administered to patients after preparation and not stored. Riboflavin losses were 
significant throughout investigation, especially when samples were stored at 
ambient temperature for two days. Riboflavin containing mixtures should be 
administered after preparation as well as mixtures with FA. Previous HPLC results 
have shown that PA degradation is small even after long time storage period. 
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Losses of this vitamin were negligible if samples stored in the fridge as well as at 
ambient temperature. 
 
It was not possible to finish the AA degradation investigation because of the 
conclusion of my research fellowship. Stability studies of AA and OA degradation 
were not complete by the time I have left, therefore it was not possible to publish 
them in this thesis.  
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ABSTRACT 
 
Malnutrition is a state in which a deficiency of energy, protein and other nutrients 
causes measurable adverse effects on tissue, body form, composition, function or 
clinical outcome1. Parenteral nutrition (PN) is an alternative method of providing 
nutritional support for patients via the intravenous route3. PN admixtures consist of 
fats, carbohydrates, proteins, vitamins, trace elements, electrolytes and fluids. 
Vitamins are believed to be among the least stable ingredients in PN mixtures and 
should be added immediately before commencing infusion. The purpose of this 
thesis was to obtain more punctual information on stability of the vitamins in 
Intralipid® emulsion depending on different storage conditions and different time. 
 
Water-soluble vitamins and fat-soluble vitamins were investigated in the mixture of 
Intralipid® emulsion (Fresenius Kabi) with Solvitio® N (water-soluble vitamins) and 
Vitlipid® N (fat-soluble vitamins) Adult Injections. There were prepared six 50ml 
Luer-Lock Syringes in total. Each of them was filled with 47 ml of the Intralipid® 
mixture and closed by Multi-Ad Luer-Lock Syringe cap. Assessing the chemical 
and physical stability was carried out after: zero time, 7, 14 and 29 days in a 
refrigerator followed by 24 and 48 hours storage at ambient temperature and day-
light protected. Physical tests included pH, osmolality, microscopy and particle 
size determination by laser diffraction. Chemical tests used validated stability 
indicating reversed phase HPLC methods. Eight vitamins were suitable for 
investigation via HPLC method, namely vitamin A and E, thiamine, pyridoxine, 
riboflavin, pantothenic acid, folic acid and nicotinamide. Ascorbic acid (AA) was 
eluted very early in gradient run and was not suitable for analysing by HPLC 
method used. 
 
AA is rapidly oxidised, the oxidation of AA clearly proceeds to inactive products. 
There is potential appearance of oxalic acid (OA) in the mixture as an end stage 
degradation product2. The purpose of my investigation was to prove the presence 
of OA as a degradation product of AA dissolved in water after couple-day storage 
at ambient temperature via HPLC analysis.  
 
According to the Laser diffraction results no lipid droplets in Intralipid® Syringes 
samples were enlarged. In discussed trials the volume of droplets bigger than 5 
µm was 0 %. Concerning the lipid globules size this Intralipid® admixture could be 
used for intravenou delivery during  whole storage period. Vitamin A in the mixture 
with fat emulsion was shown quite stable if its samples stored in the fridge. Losses 
of the vitamin E were not rapid in the mixture with fat emulsion. One of the reasons 
could be that Syringes used for storage of the mixtures are made from 
polypropylene/polyethylene and are PVC free. HPLC results have shown that 
degradation of pyridoxine is negligible when the samples are light-protected. 
Pyridoxine was shown as a stable vitamin, because its losses were small during 
whole storage period. NA HPLC results have shown that its losses during storage 
in the fridge were small. More significant degradation of NA was noticed after two 
days storage at ambient temperature. Thiamine was shown to be stable in the 
mixture with fat emulsion. Almost no losses were detected when thiamine 
containing samples were stored in the fridge. 
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HPLC results have shown that FA was rapidly degraded when the samples were 
stored out of the fridge. Losses of FA in the mixture with fat emulsion were less if 
the samples stored in the fridge. Riboflavin losses were significant throughout 
investigation, especially when samples were stored at ambient temperature for two 
days. Degradation of PA was small even after long time storage period. Losses of 
this vitamin were negligible if samples stored in the fridge as well as at ambient 
temperature. 
 
 
It was not possible to finish the AA degradation investigation because of the 
conclusion of my research fellowship. Stability studies of AA and OA degradation 
were not complete by the time I have left, therefore it was not possible to publish 
them in this thesis.  
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ABSTRAKT 
 
Podvýživa je stav, ve kterém nedostatek energie, proteinů a ostatních živin má 
znatelně nepříznivý dopad na tkáně, jejich funkci a složení1. Parenterální výživa je 
alternativní metoda poskytování nutriční podpory pro pacienty prostřednictvím 
žilního systému3. Směsi parenterální výživy se skládají z tuků, sacharidů, proteinů, 
vitamínů, stopových prvků, elektrolytů a tekutin. Vitamíny jsou považovány za 
nejméně stabilní složky v parenterálních směsích, a tudíž by měly být přidány 
bezprostředně před aplikací infuze. Cílem mé práce bylo získat informace o 
stabilitě vitamínů ve směsi Intralipid® v závislosti na různých skladovacích 
podmínkách a na době skladování. 
 
Vitamíny rozpustné ve vodě a v tucích byly testovány ve směsi Intralipid® emulze 
(Fresenius Kabi) se substancí Solvitio® N obsahující vitamíny rozpustné ve vodě a 
s emulzí obsahující vitamíny rozpustné v tucích-Vitlipid® N. Celkem bylo 
připraveno šest 50ml injekčních stříkaček. Každá z nich byla naplněna 47 ml 
Intralipidové směsi a uzavřena. Testování chemické a fyzikální stability bylo 
provedeno v čase nula, po 7, 14 a 29 dnech skladování v lednici následované 24 a 
48 hodinovým skladováním těchto směsí při okolní teplotě. Provedené fyzikální 
testy zahrnovaly měření hodnot pH, osmolality, mikroskopii, a měření velikosti 
částic laserovou difrakcí. K chemickým testům byly použity validované a stabilitu 
určující metody HPLC s užitím reverzní fáze. Pomocí HPLC bylo možno testovat 
osm vitamínů, konkrétně vitamíny A a E, thiamin, riboflavin, pyridoxin, kyselinu 
listovou, kyselinu pantothenovou a nicotinamid. Jelikož vitamín C byl eluován brzy 
v gradientové eluci, nebylo možné provést jeho analýzu pomocí popsané HPLC 
metody.  
 
Kyselina askorbová je rychle oxidována na neaktivní produkty. Existuje zde 
potencionální možnost přítomnosti oxalové kyseliny ve směsi jako konečného 
degradačního produktu2. Cílem analýzy bylo dokázat přítomnost oxalové kyseliny 
jako degradačního produktu askorbové kyseliny rozpuštěné ve vodě po několika 
dnech skladování při okolní teplotě prostřednictvím HPLC analýzy.   
 
Podle výsledků laserové difrakce, ve vzorku s Intralipidovou směsí, nebyla žádná 
z lipidových částic zvětšená. V provedených testech byl objem lipidových částic 
větších než 5 µm roven 0%. Co se týká velikosti lipidových globulí, Intralipidová 
směs by mohla být použita pro intravenozní aplikaci ve všech zkoušených 
časových jednotkách. Vitamín A byl ve směsi s tukovou emulzí zhodnocen jako 
stabilní, pokud byly analyzované vzorky uchovávány po dobu skladování v lednici. 
Ztráty vitamínu E ve směsi s tukovou emulzí nebyly rapidní. Jedním z důvodů by 
mohlo být, že stříkačky, použité pro skladování analyzovaných směsí, byly 
utvořeny z polypropylenu/polyethylenu, bez obsahu PVC. Výsledky HPLC analýzy 
ukázaly, že degradace pyridoxinu byla zanedbatelná, když vzorky byly chráněny 
před světlem a ztráty vitamínu byly nepatrné během celé doby skladování. 
Výsedky HPLC analýzy NA ukázaly, že jeho ztráty během skladování v lednici byly 
malé. Rozsáhlejší degradace NA byla zaznamenána po dvou dnech skladování 
směsi při pokojové teplotě. Thiamin byl ve směsi s tukovou emulzí zhodnocen jako 
stabilní. Téměř žádné ztráty tohoto vitamínu nebyly zaznamenány, pokud směsi 
byly uchovávány v lednici.  
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HPLC analýza kyseliny listové ukázala rychlou degradaci vitamínu, pokud směsi 
byly uchovávány při pokojové teplotě. Ztráty kyseliny listové nebyly tak výrazné, 
pokud vzorky směsi byly uchovávány v lednici. Degradace riboflavinu byla 
zaznamenána po celou dobu skladování směsí, zejména pokud byly vzorky 
uchovávány po dva dny při pokojové teplotě. Degradace kyseliny pantothenové 
byla zanedbatelná dokonce i po dlouhé skladovací době. Vliv skladovací teploty 
na degradaci vitamínu nebyl prokázán. 
 
Z důvodu nedostatku času nebylo možné dokončit analýzu degradace kyseliny 
askorbové. Studijní stáž byla ukončena před dokončením stabilitních studií 
degradace kyseliny askorbové a kyseliny oxalové, tudíž nekompletní výsledky 
nebylo možné v této práci publikovat.  
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